Synthesis of .alpha.-substituted-aryl ethylamines
    7.
    发明授权
    Synthesis of .alpha.-substituted-aryl ethylamines 失效
    α-取代的芳基乙胺的合成

    公开(公告)号:US5530125A

    公开(公告)日:1996-06-25

    申请号:US290894

    申请日:1994-08-19

    CPC分类号: C07D223/16

    摘要: A novel process for the preparation of .alpha.-substituted arylacetamides wherein the substituent is an aromatic group or a 1-alkenyl or 1-cycloalkenyl group and wherein the nitrogen atom carries no hydrogen atoms comprises the reaction of an arylacetamide having one or two hydrogen atoms on the .alpha.-carbon atom, wherein the nitrogen atom carries no hydrogen atoms, with a strong base in an inert aprotic organic solvent, followed by reaction with a zerovalent transition metal catalyst and then with a compound of the formula R.sup.4 --X, wherein R.sup.4 is selected from aromatic groups, 1-alkenyl groups and 1-cycloalkenyl groups and X is a particular leaving group, especially a triflate group. The .alpha.-substituted arylacetamides are useful as intermediates in the preparation (by reduction) of .alpha.-substituted arylethylamines, e.g., 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines, having pharmacological activity. Certain benzazepines wherein the 1-substituent R.sup.4 is 1-(1-cycloalkenyl) are novel.

    摘要翻译: PCT No.PCT / US93 / 01425 Sec。 371日期:1994年8月19日 102(e)日期1994年8月19日PCT提交1993年2月23日PCT公布。 公开号WO93 / 16997 日期:1993年9月2日。一种制备α-取代芳基乙酰胺的新方法,其中取代基是芳基或1-烯基或1-环烯基,其中氮原子不携带氢原子包括芳基乙酰胺 在α-碳原子上具有一个或两个氢原子,其中氮原子不携带氢原子,在惰性非质子有机溶剂中具有强碱,随后与零价过渡金属催化剂反应,然后与式 R4-X,其中R4选自芳族基团,1-烯基和1-环烯基,X是特定的离去基团,特别是三氟甲磺酸酯基团。 α-取代的芳基乙酰胺可用作制备(通过还原)具有药理活性的α-取代的芳基乙胺,例如1-取代-2,3,4,5-四氢-1H-3-苯并氮杂的中间体。 其中1-取代基R4是1-(1-环烯基)的某些苯并氮杂是新的。

    Substituted benzazepines, their preparation and pharmaceutical
compositions containing them
    9.
    发明授权
    Substituted benzazepines, their preparation and pharmaceutical compositions containing them 失效
    取代苯并吖庚因,其制剂和含有它们的药物组合物

    公开(公告)号:US5015639A

    公开(公告)日:1991-05-14

    申请号:US322801

    申请日:1989-03-13

    摘要: Disclosed herein are novel 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines of the general formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are specified substituents.R.sup.1 is preferably --X.sup.6, --CHR.sup.7 R.sup.8, cycloalkyl, cycloalkenyl, ##STR2## or pyrrolyl where m is 1, R.sup.6 represents .dbd.H, phenyl, substituted phenyl, aralkyl, alkyl, cycloalkyl, haloalkyl or alkoxyalkyl, R.sup.7 represents H or alkyl preferably H, R.sup.8 represents cycloalkyl, cycloalkenyl, haloalkyl, alkoxyalkyl, alkenyl or alkynyl and R.sup.9 represents alkyl, aloxy or alkoxyalkyl.R.sup.2 preferably represents --H and R.sup.3 --CH.sub.3, and R.sup.4 is preferably halogen and R.sup.5 is preferably OH, OCO.R.sup.9 or --O(CR.sup.7).sub.2.OCO.R.sup.13 where R.sup.7 represents hydrogen, R.sup.9 is as defined above and R.sup.13 represents alkyl. The compounds of the formula I are indicated as being useful in the treatment of psychoses, depression and pain. Also disclosed are process for the preparation of the novel compounds as well as pharmaceutical compositions comprising them.

    摘要翻译: 本文公开了通式I的新的1-取代-2,3,4,5-四氢-1H-3-苯并吖庚因:其中R 1,R 2,R 3,R 4和R 5是指定的取代基。 R1优选为-X6,-CHR7R8,环烷基,环烯基,或吡咯基,其中m为1,R6表示= H,苯基,取代的苯基,芳烷基,烷基,环烷基,卤代烷基或烷氧基烷基,R7表示H或烷基, R8表示环烷基,环烯基,卤代烷基,烷氧基烷基,烯基或炔基,R9代表烷基,氧基或烷氧基烷基。 R2优选表示-H和R3-CH3,R4优选为卤素,R5优选为OH,OCO.R9或-O(CR7)2.OCO.R13,其中R7表示氢,R9如上所定义,R13表示烷基。 式I化合物表示可用于治疗精神病,抑郁症和疼痛。 还公开了制备新化合物的方法以及包含它们的药物组合物。

    Substituted benzazepines useful as intermediates for producing
pharmaceutically active compounds
    10.
    发明授权
    Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds 失效
    取代苯并吖庚因可用作生产药物活性化合物的中间体

    公开(公告)号:US5247080A

    公开(公告)日:1993-09-21

    申请号:US646574

    申请日:1991-02-21

    摘要: Disclosed herein are novel compounds of formula II ##STR1## and pharmaceutically acceptable salts thereof, wherein: Q represents H, halo or --OSO.sub.2 R" wherein R" is CH.sub.3, CF.sub.3, phenyl or tolyl;R.sup.3a represents H, alkyl, allyl, cyclopropylmethyl or COOR.sup.14 wherein R.sup.14 is alkyl, aryl, aralkyl or haloalkyl;R.sup.4 represents H, halo, alkyl, haloalkyl or alkoxy;R.sup.5a represents --OR.sup.10, --N(R.sup.9).sub.2, --O--C(R.sup.7).sub.2 .multidot.OCOR.sup.13, or alkoxy; wherein each R.sup.9 independently represents H, alkyl, alkoxy, alkoxyalkyl, aralkyl or aryl;R.sup.10 represents H, --COR.sup.9 or --CON(R.sup.9).sub.2 ; andR.sup.13 represents alkyl, aralkyl or aryl,with the proviso that R.sup.3a can not be hydrogen or alkyl when Q is hydrogen, R.sup.4 is hydrogen, and R.sup.5a is hydroxy.Compounds of formula II are useful intermediates for producing compounds having valuable pharmaceutical properties in treating psychosis, depression, pain and hypertension.

    摘要翻译: 本文公开了新的式II化合物及其药学上可接受的盐,其中:Q表示H,卤素或-OSO 2 R“,其中R”为CH 3,CF 3,苯基或甲苯基; R3a代表H,烷基,烯丙基,环丙基甲基或COOR14,其中R14是烷基,芳基,芳烷基或卤代烷基; R4表示H,卤素,烷基,卤代烷基或烷氧基; R5a代表-OR10,-N(R9)2,-O-C(R7)2xOCOR13或烷氧基; 其中每个R 9独立地表示H,烷基,烷氧基,烷氧基烷基,芳烷基或芳基; R 10表示H,-COR 9或-CON(R 9)2; R 13表示烷基,芳烷基或芳基,条件是当Q为氢时,R 3a不能为氢或烷基,R4为氢,R5a为羟基。 式II化合物是制备具有治疗精神病,抑郁症,疼痛和高血压的有价值药物性质的化合物的有用中间体。